Alithea Genomics raises CHF 1 Million in seed financing round to enable commercialization and scale-up of unique RNA sequencing technology
24.05.2022
Alithea Genomics, a fast-growing, emerging leader in the field of RNA sequencing and transcriptomics analysis, announced the closing of a CHF 1 million seed financing round led by the Novalis Biotech Acceleration fund, with the participation of Swiss-based private investors.
 Riccardo Dainese, CEO, and co-founder of Alithea Genomics
|
 |
Alithea has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation of hundreds of RNA samples for sequencing in a single tube. RNA sequencing examines the quantity and sequences of RNA in a biological sample using next-generation sequencing (NGS). This data specifies which genes encoded in DNA are turned on or off, and to what extent, e.g., in a diseased cell or in response to a drug. The traditional preparation of samples for RNA sequencing is expensive and time-consuming due to the large amounts of reagents and manual operations that are typically required.
By drastically decreasing the cost and time associated with library preparation for RNA sequencing, Alithea believes the BRB-seq technology will be an essential tool in existing biomedical research sectors and in new RNA-dependent application fields. The financing proceeds will be used to expand the commercialization and scale-up of its new products, MERCURIUS™ BRB-seq and MERCURIUS™ Blood BRB-seq, a revolutionary approach to enable effective RNA sequencing from blood samples.
“Following the successful initial launch of BRB-seq and associated kits, we are now ready to expand and scale-up commercialization. This seed financing will enable us to initiate and deliver on these ambitious plans,” said Riccardo Dainese, CEO, and co-founder of Alithea Genomics. “We are grateful to Novalis and our private investors, not only for their investment but also for the shared vision of a successful future for Alithea.”Following the successful initial launch of BRB-seq and associated kits, we are now ready to expand and scale-up commercialization. This seed financing will enable us to initiate and deliver on these ambitious plans,” said Riccardo Dainese, CEO, and co-founder of Alithea Genomics. “We are grateful to Novalis and our private investors, not only for their investment but also for the shared vision of a successful future for Alithea.”
Alithea Genomics was founded in May 2020 at the EPFL in Lausanne, Switzerland. In 2021, Alithea Genomics won Venture Kick stage 3 and participated in Venture Leaders Biotech.
"Venture Leaders Biotech is more than a week of pitching and networking. It is a deep dive into the amazing biotech ecosystem overseas where every life science and biotech company can benefit from new contacts, partners, investors, and ideas!" said Riccardo Dainese.
By drastically decreasing the cost and time associated with library preparation for RNA sequencing, Alithea believes the BRB-seq technology will be an essential tool in existing biomedical research sectors and in new RNA-dependent application fields. The financing proceeds will be used to expand the commercialization and scale-up of its new products, MERCURIUS™ BRB-seq and MERCURIUS™ Blood BRB-seq, a revolutionary approach to enable effective RNA sequencing from blood samples.
“Following the successful initial launch of BRB-seq and associated kits, we are now ready to expand and scale-up commercialization. This seed financing will enable us to initiate and deliver on these ambitious plans,” said Riccardo Dainese, CEO, and co-founder of Alithea Genomics. “We are grateful to Novalis and our private investors, not only for their investment but also for the shared vision of a successful future for Alithea.”Following the successful initial launch of BRB-seq and associated kits, we are now ready to expand and scale-up commercialization. This seed financing will enable us to initiate and deliver on these ambitious plans,” said Riccardo Dainese, CEO, and co-founder of Alithea Genomics. “We are grateful to Novalis and our private investors, not only for their investment but also for the shared vision of a successful future for Alithea.”
Alithea Genomics was founded in May 2020 at the EPFL in Lausanne, Switzerland. In 2021, Alithea Genomics won Venture Kick stage 3 and participated in Venture Leaders Biotech.
"Venture Leaders Biotech is more than a week of pitching and networking. It is a deep dive into the amazing biotech ecosystem overseas where every life science and biotech company can benefit from new contacts, partners, investors, and ideas!" said Riccardo Dainese.